A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Phase 1/2 Completed 57 enrolled AC Immune SA Janssen Research & Development, LLC · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.

Timeline

Start: 2019-07-31
Primary completion: 2023-09-05
Completion: 2023-09-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACI-35.030	Unknown	—	—
Subject	JACI-35.054	Unknown	—	—

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Summary

Timeline

Drugs

Indications